141 related articles for article (PubMed ID: 32979704)
21. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
DeMichele A; Clark AS; Tan KS; Heitjan DF; Gramlich K; Gallagher M; Lal P; Feldman M; Zhang P; Colameco C; Lewis D; Langer M; Goodman N; Domchek S; Gogineni K; Rosen M; Fox K; O'Dwyer P
Clin Cancer Res; 2015 Mar; 21(5):995-1001. PubMed ID: 25501126
[TBL] [Abstract][Full Text] [Related]
22. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
Abraham J; Coleman R; Elias A; Holmes FA; Kalinsky K; Kittaneh M; Lower E; Mahtani R; Terry Mamounas E; Pegram M; Vogel C;
Breast Cancer Res Treat; 2018 Aug; 171(1):11-20. PubMed ID: 29725889
[TBL] [Abstract][Full Text] [Related]
23. CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.
Messina C; Cattrini C; Buzzatti G; Cerbone L; Zanardi E; Messina M; Boccardo F
Breast Cancer Res Treat; 2018 Nov; 172(1):9-21. PubMed ID: 30054831
[TBL] [Abstract][Full Text] [Related]
24. CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases.
Figura NB; Potluri TK; Mohammadi H; Oliver DE; Arrington JA; Robinson TJ; Etame AB; Tran ND; Liu JK; Soliman H; Forsyth PA; Sahebjam S; Yu HM; Han HS; Ahmed KA
J Neurooncol; 2019 Sep; 144(3):583-589. PubMed ID: 31399935
[TBL] [Abstract][Full Text] [Related]
25. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
26. Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis.
Schettini F; Giudici F; Giuliano M; Cristofanilli M; Arpino G; Del Mastro L; Puglisi F; De Placido S; Paris I; De Placido P; Venturini S; De Laurentis M; Conte P; Juric D; Llombart-Cussac A; Pusztai L; Prat A; Jerusalem G; Di Leo A; Generali D
J Natl Cancer Inst; 2020 Nov; 112(11):1089-1097. PubMed ID: 32407488
[TBL] [Abstract][Full Text] [Related]
27. Palbociclib in advanced stage hormone receptor-positive breast cancer: real-world data from a Chilean multicentre registry.
Walbaum B; Reyes JM; Rodriguez P; Muñiz S; Medina L; Ibañez C; Merino T; Pinto MP; Bravo ML; Acevedo F; Bennett J; Sanchez C
Ecancermedicalscience; 2023; 17():1636. PubMed ID: 38414945
[TBL] [Abstract][Full Text] [Related]
28. Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer.
Princic N; Aizer A; Tang DH; Smith DM; Johnson W; Bardia A
Curr Med Res Opin; 2019 Jan; 35(1):73-80. PubMed ID: 30175631
[No Abstract] [Full Text] [Related]
29. Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.
Dawood S; Chiu JW; Huang CS; Nag S; Sookprasert A; Yap YS; Md Yusof M
Curr Med Res Opin; 2020 Aug; 36(8):1363-1373. PubMed ID: 32544344
[TBL] [Abstract][Full Text] [Related]
30. Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Burris HA
Expert Rev Anticancer Ther; 2018 Mar; 18(3):201-213. PubMed ID: 29457921
[TBL] [Abstract][Full Text] [Related]
31. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
Turner NC; Ro J; André F; Loi S; Verma S; Iwata H; Harbeck N; Loibl S; Huang Bartlett C; Zhang K; Giorgetti C; Randolph S; Koehler M; Cristofanilli M;
N Engl J Med; 2015 Jul; 373(3):209-19. PubMed ID: 26030518
[TBL] [Abstract][Full Text] [Related]
32. [Inhibitors of cyclin-dependent kinases (CDK) - a new group of medicines in therapy of advanced breast cancer].
Sarosiek T
Pol Merkur Lekarski; 2018 Jan; 44(259):5-9. PubMed ID: 29374415
[TBL] [Abstract][Full Text] [Related]
33. Targeting CDK4/6 pathways and beyond in breast cancer.
Ribnikar D; Volovat SR; Cardoso F
Breast; 2019 Feb; 43():8-17. PubMed ID: 30359883
[TBL] [Abstract][Full Text] [Related]
34. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
35. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions.
Spring L; Bardia A; Modi S
Discov Med; 2016 Jan; 21(113):65-74. PubMed ID: 26896604
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
Finn RS; Crown JP; Ettl J; Schmidt M; Bondarenko IM; Lang I; Pinter T; Boer K; Patel R; Randolph S; Kim ST; Huang X; Schnell P; Nadanaciva S; Bartlett CH; Slamon DJ
Breast Cancer Res; 2016 Jun; 18(1):67. PubMed ID: 27349747
[TBL] [Abstract][Full Text] [Related]
37. CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care.
Hui R; de Boer R; Lim E; Yeo B; Lynch J
Asia Pac J Clin Oncol; 2021 Jan; 17 Suppl 1():3-14. PubMed ID: 33506626
[TBL] [Abstract][Full Text] [Related]
38. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
Sammons S; Shastry M; Dent S; Anders C; Hamilton E
Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
[TBL] [Abstract][Full Text] [Related]
39. Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian population.
Agrawal C; Goyal P; Agarwal A; Tripathi R; Dodagoudar C; Baghmar S; Sharma A; Batra U; Talwar V; Goyal S; Kumar R; Doval DC
Sci Rep; 2021 Aug; 11(1):16236. PubMed ID: 34376758
[TBL] [Abstract][Full Text] [Related]
40. Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer.
Lim E; Beith J; Boyle F; de Boer R; Hui R; McCarthy N; Redfern A; Wade T; Woodward N
Asia Pac J Clin Oncol; 2018 Oct; 14 Suppl 4():12-21. PubMed ID: 30288929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
